CL2020002719A1 - Moduladores de nlrp3 - Google Patents

Moduladores de nlrp3

Info

Publication number
CL2020002719A1
CL2020002719A1 CL2020002719A CL2020002719A CL2020002719A1 CL 2020002719 A1 CL2020002719 A1 CL 2020002719A1 CL 2020002719 A CL2020002719 A CL 2020002719A CL 2020002719 A CL2020002719 A CL 2020002719A CL 2020002719 A1 CL2020002719 A1 CL 2020002719A1
Authority
CL
Chile
Prior art keywords
nlrp3
modulators
nlrp3 modulators
compounds
medicaments
Prior art date
Application number
CL2020002719A
Other languages
English (en)
Inventor
Zhang Yong
V Gavai Ashvinikumar
F Donnell Andrew
Ghosh Shomir
R Roush William
Sivaprakasam Prasanna
P Seitz Steven
A Markwalder Jay
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of CL2020002719A1 publication Critical patent/CL2020002719A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

La presente invención proporciona compuestos de Fórmula (I): en el que todas las variables son como se definen en el presente documento. Estos compuestos son moduladores de NLRP3, que pueden ser utilizados como medicamentos para el tratamiento de trastornos proliferativos, tales como cáncer en un sujeto (por ejemplo, un ser humano).
CL2020002719A 2018-04-25 2020-10-21 Moduladores de nlrp3 CL2020002719A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662240P 2018-04-25 2018-04-25
US201862764818P 2018-08-16 2018-08-16
US201962825044P 2019-03-28 2019-03-28

Publications (1)

Publication Number Publication Date
CL2020002719A1 true CL2020002719A1 (es) 2020-12-18

Family

ID=66677224

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002719A CL2020002719A1 (es) 2018-04-25 2020-10-21 Moduladores de nlrp3

Country Status (19)

Country Link
US (1) US12037344B2 (es)
EP (2) EP3784670B1 (es)
JP (2) JP7351850B2 (es)
KR (1) KR102711180B1 (es)
CN (2) CN112521387B (es)
AU (1) AU2019261582A1 (es)
BR (1) BR112020021539A2 (es)
CA (1) CA3097865A1 (es)
CL (1) CL2020002719A1 (es)
CO (2) CO2020013155A2 (es)
ES (1) ES2971122T3 (es)
IL (1) IL278173A (es)
MX (1) MX2020011234A (es)
NZ (1) NZ769136A (es)
PE (1) PE20210160A1 (es)
SG (1) SG11202010463TA (es)
TW (1) TW202014420A (es)
WO (1) WO2019209896A1 (es)
ZA (1) ZA202007307B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087842A1 (en) * 2020-01-10 2022-11-16 Innate Tumor Immunity, Inc. Nlrp3 modulators
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
IL297165A (en) * 2020-04-16 2022-12-01 Incyte Corp Soysag tricyclic CRS inhibitors
KR20230005320A (ko) 2020-04-30 2023-01-09 얀센 파마슈티카 엔.브이. 신규 트리아지노인돌 화합물
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
AU2021279305A1 (en) * 2020-05-28 2023-02-09 Janssen Pharmaceutica Nv Compounds
CN116390923B (zh) * 2020-08-21 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和用途
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP3984535A1 (en) * 2020-10-16 2022-04-20 Albert-Ludwigs-Universität Freiburg Nlrp3 activators for use in the treatment of infectious diseases or cancer by activating nlrp3 inflammasome
WO2022115377A1 (en) * 2020-11-24 2022-06-02 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
CN114539095A (zh) * 2020-11-26 2022-05-27 乐凯化学材料有限公司 3-（4-羟基-3-甲氧基-苯基）-2-氰基-2-丙烯酸乙酯的制备方法
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
CA3224674A1 (en) 2021-07-07 2023-01-12 Pei Gan Tricyclic compounds as inhibitors of kras
CN117940120A (zh) * 2021-07-16 2024-04-26 戴纳立制药公司 化合物、组合物和方法
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors
WO2025190317A1 (en) * 2024-03-13 2025-09-18 National Institute Of Biological Sciences, Beijing Urea compounds as nlrp3 agonists
WO2026006603A1 (en) * 2024-06-26 2026-01-02 Wisconsin Alumni Research Foundation Tlr7/tlr8 agonists for use in trifunctional radiopharmaceutical compounds

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
NZ546274A (en) 2003-10-03 2009-12-24 3M Innovative Properties Co Pyrazolopyridines and analags thereof
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20070259907A1 (en) 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
WO2007120121A2 (en) 2005-02-09 2007-10-25 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
EP2188285A1 (en) 2007-08-14 2010-05-26 Novartis Ag Pyrazoloquinoline and pyrazolonaphthyridine derivatives as gaba alpha ligands
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101649610B1 (ko) 2011-04-21 2016-08-19 오리제니스 게엠베하 키나아제 억제제로서의 헤테로사이클릭 화합물
SI2573073T1 (sl) 2011-09-26 2015-02-27 Sanofi Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104418867B (zh) * 2013-08-26 2016-12-28 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
WO2016199943A1 (en) 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20180040706A (ko) 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
CN105523955B (zh) 2015-12-14 2018-08-17 北京嘉林药业股份有限公司 化合物及其在制备药物中的用途
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
US10533007B2 (en) 2016-04-19 2020-01-14 Innate Tumor Immunity, Inc. NLRP3 modulators
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CN111793060B (zh) 2017-07-14 2023-06-06 先天肿瘤免疫公司 Nlrp3调节剂
IL277978B2 (en) 2018-04-25 2024-07-01 Bayer Ag Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides

Also Published As

Publication number Publication date
JP7351850B2 (ja) 2023-09-27
AU2019261582A1 (en) 2020-11-12
ZA202007307B (en) 2023-01-25
TW202014420A (zh) 2020-04-16
JP2021522249A (ja) 2021-08-30
US20210267964A1 (en) 2021-09-02
JP7660634B2 (ja) 2025-04-11
JP2024001030A (ja) 2024-01-09
KR20210005106A (ko) 2021-01-13
CO2020013155A2 (es) 2021-06-10
CA3097865A1 (en) 2019-10-31
PE20210160A1 (es) 2021-01-26
CN112521387B (zh) 2023-08-22
BR112020021539A2 (pt) 2021-01-19
EP4353235A2 (en) 2024-04-17
MX2020011234A (es) 2020-11-11
NZ769136A (en) 2024-04-26
EP3784670A1 (en) 2021-03-03
ES2971122T3 (es) 2024-06-03
EP4353235A3 (en) 2024-07-31
EP3784670B1 (en) 2023-11-29
KR102711180B1 (ko) 2024-09-26
IL278173A (en) 2020-11-30
SG11202010463TA (en) 2020-11-27
US12037344B2 (en) 2024-07-16
CN112074516A (zh) 2020-12-11
WO2019209896A1 (en) 2019-10-31
CO2021006672A2 (es) 2021-06-10
CN112521387A (zh) 2021-03-19

Similar Documents

Publication Publication Date Title
CO2020013155A2 (es) Moduladores de nlrp3
CO2020000227A2 (es) Moduladores de nlrp3
MX2019009796A (es) Compuestos para el tratamiento del cancer.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
CO2019013016A2 (es) Inhibidores pirazólicos de magl
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
UY36077A (es) Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
DOP2021000071A (es) Compuestos heteroaromáticos como inhibidores de vanina
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
MX2020004871A (es) Derivados de acido cafeico y sus usos.
EA202092539A1 (ru) Модуляторы nlrp3
EA202090283A1 (ru) Модуляторы nlrp3